liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data
Karolinska University Hospital.
Swedish Institute for Infectious Disease Control.
Karolinska University Hospital.
Karolinska University Hospital.
Show others and affiliations
2010 (English)In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, ISSN 0305-7453, Vol. 65, no 5, 946-952 p.Article in journal (Refereed) Published
Abstract [en]

To describe wild-type distributions of the MIC of fluoroquinolones for Mycobacterium tuberculosis in relation to current critical concentrations used for drug susceptibility testing and pharmacokinetic/pharmacodynamic (PK/PD) data. A 96-stick replicator on Middlebrook 7H10 medium was used to define the MICs of ciprofloxacin, ofloxacin, moxifloxacin and levofloxacin for 90 consecutive clinical strains and 24 drug-resistant strains. The MICs were compared with routine BACTEC 460 susceptibility results and with MIC determinations in the BACTEC MGIT 960 system in a subset of strains using ofloxacin as a class representative. PK/PD data for each drug were reviewed in relation to the wild-type MIC distribution. The wild-type MICs of ciprofloxacin, ofloxacin, moxifloxacin and levofloxacin were distributed from 0.125 to 1, 0.25 to 1, 0.032 to 0.5 and 0.125 to 0.5 mg/L, respectively. The MIC data correlated well with the BACTEC 960 MGIT and BACTEC 460 results. PD indices were the most favourable for levofloxacin, followed by moxifloxacin, ofloxacin and ciprofloxacin. We propose S (susceptible) andlt; 1.0 mg/L as the tentative epidemiological cut-off (ECOFF) for ofloxacin and ciprofloxacin, and S andlt; 0.5 mg/L for levofloxacin and moxifloxacin, although it is possible that adding more MIC data could shift the ECOFFs for ofloxacin and levofloxacin one dilution upwards. The proposed ECOFFs may be more appropriate if used as clinical breakpoints on Middlebrook 7H10 agar than the current critical concentrations of S andlt; 2.0 mg/L for ciprofloxacin, ofloxacin and levofloxacin, and S andlt; 0.5 mg/L could be considered as a clinical breakpoint for moxifloxacin, provided other investigators can confirm our findings.

Place, publisher, year, edition, pages
Oxford University Press , 2010. Vol. 65, no 5, 946-952 p.
Keyword [en]
ciprofloxacin, ofloxacin, moxifloxacin, levofloxacin, susceptibility testing
National Category
Engineering and Technology
URN: urn:nbn:se:liu:diva-55052DOI: 10.1093/jac/dkq091ISI: 000276527500019OAI: diva2:315266
Available from: 2010-04-28 Created: 2010-04-28 Last updated: 2010-04-28

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Nordvall, MariaJohansson, A G
By organisation
Pediatrics Faculty of Health SciencesDepartment of Paediatrics in LinköpingDepartment of Clinical and Experimental Medicine
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 22 hits
ReferencesLink to record
Permanent link

Direct link